Amphastar Pharmaceuticals, Inc.
AMPHHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 29, 2026
Scan Results
Daily timeframeAmphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States,. At a $851.0M market cap, Amphastar Pharmaceuticals, Inc. ranks as a small-cap company within healthcare. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Market Cap
$851.0M
Beta
0.97
P/E (TTM)
11.63
P/E (Fwd)
5.89
EPS (TTM)
$1.66
EPS (Fwd)
$3.28
ROE
10.4%
ROA
5.3%
Cash
$292.0M
Total Debt
$686.4M
Free CF
$103.1M
52W Change
-24.9%
Annual Financials
Cash vs Debt
Amphastar Pharmaceuticals, Inc. carries $686.4M in total debt against $292.0M in cash reserves — debt is roughly 2.4x the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $103.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 10.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 5.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $499.0M (2022) to $719.9M (2025), reflecting a 44% increase over the period.
As with any equity investment, AMPH carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AMPH.